Company Active LTD

Company profile

Alphabiomics Ltd

AlphaBiomics Enabling safer and more efficacious drug therapies

Alphabiomics Ltd is a UK company with status active founded in 2018 based in North East England.

CRN
11232306
Founded
2018
Age
8

Overview

Legal name
ALPHABIOMICS LTD
Region
North East England
Registered address
4 QUEENSWAY
PONTELAND
NEWCASTLE UPON TYNE
ENGLAND
NE20 9RZ
Insolvency history
No

Latest accounts

Financial period: 1 Apr 2024 to 31 Mar 2025

ABRIDGEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
0

Company events

Reference milestones and recent Companies House filing stream events.

7 events
31 Dec
2027

Accounts due

Accounts Due

Next accounts due date

18 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Mar
2026

Accounts filed

Accounts

Last accounts made up date

04 Mar
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

08 Oct
2024

Accounts With Accounts Type Micro Entity

Accounts Analysed

AA | Transaction MzQzODc0NTY2M2FkaXF6a2N4

Published 08 Oct 2024 02:41

17 Sep
2024

Change Registered Office Address Company With Date Old Address New Address

Address

AD01 | Transaction MzQzNTkzOTM4NWFkaXF6a2N4

Published 17 Sep 2024 06:17

05 Mar
2018

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2022
Funded years
2022, 2024
Age at first award
4 years

Projects

2024 Collaborative R&D Lead participant

AlphaGutScan: a person-centred, AI-enhanced consumer microbiome test for personalised health insights

1 Nov 2024 to 31 Mar 2025

Awarded
£29,925
Total cost £29,925

**Introduction:** AlphaBiomics is working on a new health test called AlphaGutScan. This test lets people safely collect a simple stool (poo) sample at home and send it to the company. We will then check your gut health by looking at what's in your stool. The test uses a very detailed way of looking at the bacteria that live in your gut. It also uses smar...

2022 Grant for R&D Lead participant

UK market access strategy for AlphaBiomics’ novel precision medicine diagnostic test RxSelex™

1 Nov 2022 to 30 Apr 2023

Awarded
£49,816
Total cost £49,816

**HEALTHCARE CHALLENGE:** Immune-mediated diseases are lifelong illnesses characterized by an abnormal reaction of the body's immune system, known as inflammation. Examples are Crohn's disease (CD) and ulcerative colitis (UC). People who experience severe disease whose activity cannot be controlled with the usual medication are typically treated with a bi...

Product types

Collaborative R&D Grant for R&D